Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of micafungin versus active antifungal control in refractory or intolerant invasive aspergillosis
2005-004988-27Phase 2Terminated
- Sponsor
- Astellas Pharma BV
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of micafungin in invasive aspergillosis (IA) and aspergillosis (2 arms), sponsored by Astellas Pharma BV. Primary endpoint: Overall success at end of treatment. Started Mar 2006; status: terminated.
02
Drugs
micafungin
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on 2005-004988-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004988-27.